journal article·2023-07

Transcytosis Mediated Deep Tumor Penetration for Enhanced Chemotherapy and Immune Activation of Pancreatic Cancer

Hongyi Chen, Haolin Song, Yifan Luo, Chufeng Li, Yu Wang, Jie Liu, Feifei Luo, Hongrui Fan, Xuwen Li, Tao Sun, Chen Jiang

Advanced Functional Materials· Volume 33· Issue 28
Publisher page

Abstract

Abstract The hyperproliferative tumor stroma of pancreatic ductal adenocarcinoma (PDAC) severely limits drug permeation and constructs an immunosuppressive microenvironment, causing resistance to chemotherapy and immunotherapy. Traditional nanomedicine mainly focuses on manipulating nanoparticles’ particle size or electrical characteristics to penetrate deep PDAC through the paracellular pathway, but the transcellular pathway is often ignored. Therefore, a versatile drug‐polymer conjugate PODEA‐Gem‐HMI is prepared and assembled into nanoparticles for the codelivery of chemotherapy drug gemcitabine and focal adhesion kinase (FAK) inhibitor defactinib. While sensing the mild acidity in the tumor microenvironment, the nanoparticle will disintegrate and release defactinib to modulate the tumor stroma. The PODEA block of the conjugate can bind with cell membranes reversibly and trigger adsorption‐mediated transcytosis (AMT) for promoted tumor penetration and cellular uptake. The internalized conjugates will release gemcitabine responding to the overexpressed glutathione (GSH) for enhanced chemotherapy, and PHMI can condensate the STING monomers for prolonged spontaneous immune stimulation.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Research and Treatments · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics School of Pharmacy Key Laboratory of Smart Drug Delivery Ministry of Education State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science Fudan University Shanghai 201203 China

Department of Digestive Diseases Huashan Hospital Fudan University Shanghai 200040 China

Funding

National Natural Science Foundation of China

References (52)

Show source-provided references
1. 10.1038/s41575-021-00457-x10.1038/s41575-021-00457-x ↗
2. 10.1053/j.gastro.2022.03.05610.1053/j.gastro.2022.03.056 ↗
3. 10.1038/s41575-020-0300-110.1038/s41575-020-0300-1 ↗
4. 10.1038/s41571-020-0363-510.1038/s41571-020-0363-5 ↗
5. 10.1038/emm.2017.25510.1038/emm.2017.255 ↗
6. 10.1016/j.ccell.2021.02.00710.1016/j.ccell.2021.02.007 ↗
7. 10.1053/j.gastro.2022.02.02410.1053/j.gastro.2022.02.024 ↗
8. 10.1158/2159-8290.CD-20-148410.1158/2159-8290.CD-20-1484 ↗
9. 10.1002/adma.20170724010.1002/adma.201707240 ↗
10. 10.1002/advs.20190143010.1002/advs.201901430 ↗
11. 10.1002/advs.20210412510.1002/advs.202104125 ↗
12. 10.1021/acsnano.2c0534210.1021/acsnano.2c05342 ↗
13. 10.1016/j.jconrel.2022.12.02810.1016/j.jconrel.2022.12.028 ↗
14. 10.1002/adma.20220738410.1002/adma.202207384 ↗
15. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
16. 10.1016/j.bbcan.2020.18846110.1016/j.bbcan.2020.188461 ↗
17. 10.1038/s41563-020-0672-110.1038/s41563-020-0672-1 ↗
18. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗
19. 10.1002/advs.20220406710.1002/advs.202204067 ↗
20. 10.1016/j.biomaterials.2021.12070910.1016/j.biomaterials.2021.120709 ↗
21. 10.1016/j.cell.2022.06.03510.1016/j.cell.2022.06.035 ↗
22. 10.1007/s40820-021-00622-610.1007/s40820-021-00622-6 ↗
23. 10.1186/s40425-019-0573-510.1186/s40425-019-0573-5 ↗
24. 10.1186/s12943-020-01247-w10.1186/s12943-020-01247-w ↗
25. 10.1038/s41467-021-26240-910.1038/s41467-021-26240-9 ↗
26. 10.1126/science.abb425510.1126/science.abb4255 ↗
27. 10.1038/s41551-020-00675-910.1038/s41551-020-00675-9 ↗
28. 10.1038/nnano.2017.5210.1038/nnano.2017.52 ↗
29. 10.1136/gutjnl-2018-31742410.1136/gutjnl-2018-317424 ↗
30. 10.1186/s40425-017-0217-610.1186/s40425-017-0217-6 ↗
31. 10.15252/emmm.20201201010.15252/emmm.202012010 ↗
32. 10.1021/acsnano.0c0267410.1021/acsnano.0c02674 ↗
33. 10.1002/adma.20210716110.1002/adma.202107161 ↗
34. 10.1038/s41551-021-00701-410.1038/s41551-021-00701-4 ↗
35. 10.1002/advs.20220017310.1002/advs.202200173 ↗
36. 10.1002/adma.20210525410.1002/adma.202105254 ↗
37. 10.1038/s41565-019-0485-z10.1038/s41565-019-0485-z ↗
38. Amrutkar M. · Cancers · 2017 · 9
39. 10.1038/s41467-020-15104-310.1038/s41467-020-15104-3 ↗
40. 10.1016/j.immuni.2020.03.01010.1016/j.immuni.2020.03.010 ↗
41. 10.1016/j.ccell.2020.08.00410.1016/j.ccell.2020.08.004 ↗
42. 10.1016/j.canlet.2020.10.02910.1016/j.canlet.2020.10.029 ↗
43. 10.1038/s41392-021-00769-z10.1038/s41392-021-00769-z ↗
44. 10.1038/nm.408210.1038/nm.4082 ↗
45. 10.1038/s41419-022-05046-710.1038/s41419-022-05046-7 ↗
46. 10.1016/j.mattod.2022.11.00810.1016/j.mattod.2022.11.008 ↗
47. 10.1016/j.smim.2019.10129910.1016/j.smim.2019.101299 ↗
48. 10.3389/fimmu.2018.0044410.3389/fimmu.2018.00444 ↗
49. 10.1007/s00011-013-0633-010.1007/s00011-013-0633-0 ↗
50. 10.1126/sciimmunol.abi461310.1126/sciimmunol.abi4613 ↗
51. 10.1038/nrneph.2016.4810.1038/nrneph.2016.48 ↗
52. 10.1002/smll.20210771210.1002/smll.202107712 ↗